An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies.

ABSTRACT:

SUBMITTER: Findlay A 

PROVIDER: S-EPMC8571951 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature